Welcome to our dedicated page for Zentalis Pharmaceuticals news (Ticker: ZNTL), a resource for investors and traders seeking the latest updates and insights on Zentalis Pharmaceuticals stock.
Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL) is a clinical-stage biopharmaceutical company focused on oncology, and its news flow centers on the development of azenosertib (ZN‑c3), an investigational WEE1 inhibitor. Company updates highlight progress in Cyclin E1-positive platinum-resistant ovarian cancer (PROC), where azenosertib is the lead program, as well as exploratory work in other tumor types and combination regimens.
Visitors to this ZNTL news page can follow announcements on the DENALI Phase 2 trial, a multi-part, registration-intent study in PROC. Zentalis uses press releases to report milestones such as completion of enrollment in DENALI Part 2a, dose confirmation plans, and expectations for topline data from Part 2, which the company states could support a potential accelerated approval pathway, subject to FDA feedback. News items also describe alignment with the U.S. Food and Drug Administration on the design of ASPENOVA, a planned Phase 3 randomized, confirmatory trial comparing azenosertib to standard-of-care chemotherapy in Cyclin E1-positive PROC.
Beyond ovarian cancer, Zentalis news covers scientific presentations and broader development activity for azenosertib, including Phase 1 data in advanced solid tumors, Cyclin E1 biomarker findings, the TETON Phase 2 trial in uterine serous carcinoma, and a Phase 1 combination study with trastuzumab deruxtecan in HER2-expressing cancers. The company also issues regular financial results and operational progress releases, detailing research and development spending, cash position, and restructuring steps intended to prioritize late-stage development of azenosertib.
Additional ZNTL headlines include corporate governance and personnel changes, such as leadership transitions in the Chief Legal Officer role, board resignations, and equity inducement grants under Nasdaq Listing Rule 5635(c)(4). Investors and observers can use this page to monitor how Zentalis links its clinical milestones, biomarker strategy and financial resources as it advances azenosertib in PROC and other tumor settings.
Zentalis (Nasdaq: ZNTL) provided a corporate update on January 6, 2026 outlining 2026 milestones for azenosertib, its investigational WEE1 inhibitor for Cyclin E1-positive platinum-resistant ovarian cancer (PROC). Key points: DENALI Part 2a enrollment completed with dose confirmation expected in 1H 2026, DENALI Part 2 topline readout expected by year-end 2026 (could support accelerated approval, subject to FDA feedback), and initiation of the randomized Phase 3 ASPENOVA trial planned in 1H 2026. The company reported $280.7M cash and equivalents as of Sept 30, 2025, providing an estimated runway into late 2027.
Zentalis (Nasdaq: ZNTL) reported third quarter 2025 results and operational updates on Nov 10, 2025. The company has $280.7 million in cash, cash equivalents and marketable securities, which it says provides runway into late 2027. The Phase 2 DENALI trial of azenosertib in Cyclin E1-positive platinum-resistant ovarian cancer remains on track with topline data from Part 2 expected by year-end 2026 and potential to support accelerated approval, subject to FDA feedback. Enrollment completed in the TETON Phase 2 uterine serous carcinoma trial; results are planned for publication in first half 2026. Quarterly operating expenses declined to $33.7M.
Zentalis Pharmaceuticals (Nasdaq: ZNTL) announced on November 3, 2025 that its Compensation Committee granted non-qualified stock options to purchase an aggregate of 17,000 shares to one newly hired employee as an inducement under the 2022 Inducement Plan pursuant to Nasdaq Listing Rule 5635(c)(4).
The options carry an exercise price of $1.44 per share (closing price on the grant date), have a 10-year term, and vest over 4 years (25% after one year, then monthly over three years) subject to continued service.
Zentalis Pharmaceuticals (Nasdaq: ZNTL) said management will participate in two investor events in November 2025: a Guggenheim Healthcare Innovation fireside on Nov 11, 2025 at 3:30 p.m. ET and a Stifel Healthcare presentation on Nov 12, 2025 at 8:00 a.m. ET.
Live webcasts and archived recordings will be available under the Events & Presentations tab on the company Investor & Media website. The company is a clinical-stage biopharma developing a WEE1 inhibitor for ovarian cancer and other tumors.
Zentalis (Nasdaq: ZNTL) announced four azenosertib poster presentations at the AACR‑NCI‑EORTC International Conference on Molecular Targets and Cancer Therapeutics, held October 22–26, 2025 in Boston.
Presentations include Phase 1 dose escalation/expansion results, Cyclin E1 biomarker findings supporting late‑stage development in Cyclin E1‑positive platinum‑resistant ovarian cancer (noted as ~50% of PROC), a trial‑in‑progress DENALI Part 2 biomarker study (GOG‑3066), and a trastuzumab deruxtecan + azenosertib combination study in HER2‑expressing tumors. Posters are scheduled October 23–24, 2025 and will be available via Zentalis' Publications page on the presentation days.
Zentalis Pharmaceuticals (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing WEE1 inhibitors for ovarian cancer treatment, has announced equity inducement grants. The company granted non-qualified stock options to newly hired employees, including 400,000 shares to James B. Bucher, the new Chief Legal Officer, and 15,000 shares to two additional employees.
The options, granted under the 2022 Inducement Plan, have an exercise price of $1.54 per share and a 10-year term. They will vest over four years, with 25% vesting after the first year and the remaining 75% vesting monthly over three years, subject to continued employment.
Zentalis Pharmaceuticals (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on developing a WEE1 inhibitor for ovarian cancer treatment, has announced inducement grants under its 2022 Employment Inducement Incentive Award Plan. The company granted stock options for 381,000 shares to six new employees.
The options, priced at $1.72 per share, will vest over four years with 25% vesting in the first year and the remaining 75% vesting monthly over three years. These grants, approved by the Compensation Committee, comply with Nasdaq Listing Rule 5635(c)(4) and are designed to attract new talent to the company.
Zentalis Pharmaceuticals (NASDAQ: ZNTL), a clinical-stage biopharmaceutical company, will participate in three major investor conferences in September 2025. The company, which is developing a potentially first-in-class WEE1 inhibitor for ovarian cancer and other tumor types, will present at:
- Wells Fargo Healthcare Conference (Boston) - September 4, 10:15 AM ET
- H.C. Wainwright Global Investment Conference (New York) - September 8, 2:30 PM ET
- Morgan Stanley Global Healthcare Conference (New York) - September 9, 7:00 AM ET
Live webcasts and recordings will be available on the company's website under the "Events & Presentations" section.
Zentalis Pharmaceuticals (Nasdaq: ZNTL) has appointed James B. Bucher, JD as Chief Legal Officer and Corporate Secretary, effective September 18, 2025. Bucher brings over 30 years of life sciences legal experience, most recently serving as Chief Legal Officer at Harpoon Therapeutics where he led the company's acquisition by Merck in 2024.
He succeeds Andrea Paul, who served since 2022 and is departing to join an international law firm. Bucher's extensive experience includes corporate strategy, governance, capital raising, and M&A, having overseen more than $1 billion in capital raising at Exelixis and playing a key role in Alder Biopharmaceuticals' $2.4 billion acquisition by Lundbeck.
The appointment comes as Zentalis advances registration-intent clinical trials for azenosertib, their potentially first-in-class and best-in-class WEE1 inhibitor for ovarian cancer treatment.
Zentalis Pharmaceuticals (NASDAQ:ZNTL) reported Q2 2025 financial results and provided updates on its clinical progress. The company's lead candidate azenosertib is advancing in the Phase 2 DENALI trial for Cyclin E1-positive platinum-resistant ovarian cancer (PROC), with topline data expected by year-end 2026.
The company maintains a strong financial position with $303.4 million in cash and equivalents, providing runway into late 2027. Operating expenses decreased to $36.1 million from $65.1 million year-over-year, reflecting the company's strategic restructuring announced in January 2025. R&D expenses decreased to $27.6 million from $48.4 million in the prior year.
FAQ
What is the current stock price of Zentalis Pharmaceuticals (ZNTL)?
What is the market cap of Zentalis Pharmaceuticals (ZNTL)?
